288 related articles for article (PubMed ID: 17988233)
1. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
[TBL] [Abstract][Full Text] [Related]
2. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
N Engl J Med; 2003 Feb; 348(9):800-7. PubMed ID: 12606734
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Perrillo R; Schiff E; Yoshida E; Statler A; Hirsch K; Wright T; Gutfreund K; Lamy P; Murray A
Hepatology; 2000 Jul; 32(1):129-34. PubMed ID: 10869300
[TBL] [Abstract][Full Text] [Related]
5. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
[TBL] [Abstract][Full Text] [Related]
6. Treatment of HBeAg-negative chronic hepatitis B.
Hadziyannis SJ; Papatheodoridis GV; Vassilopoulos D
Semin Liver Dis; 2003 Feb; 23(1):81-8. PubMed ID: 12616453
[TBL] [Abstract][Full Text] [Related]
7. Advances in therapy for chronic hepatitis B.
Marcellin P
Semin Liver Dis; 2002; 22 Suppl 1():33-6. PubMed ID: 12447727
[TBL] [Abstract][Full Text] [Related]
8. [New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
Petry W; Erhardt A; Heintges T; Häussinger D
Z Gastroenterol; 2000 Jan; 38(1):77-87. PubMed ID: 10689749
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.
Tillmann HL; Bock CT; Bleck JS; Rosenau J; Böker KH; Barg-Hock H; Becker T; Trautwein C; Klempnauer J; Flemming P; Manns MP
Liver Transpl; 2003 Feb; 9(2):191-6. PubMed ID: 12548514
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Vig P; Gibbs CS; Brosgart C; Fry J; Namini H; Katlama C; Poynard T
Lancet; 2001 Sep; 358(9283):718-23. PubMed ID: 11551579
[TBL] [Abstract][Full Text] [Related]
11. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
12. Predominance of pre-S1 mutated hepatitis B virus in a patient following treatment with adefovir dipivoxil.
Villa E; Boarino V; Grottola A; Gelmini R; Lama NG
Liver Transpl; 2003 Feb; 9(2):188-90. PubMed ID: 12548513
[TBL] [Abstract][Full Text] [Related]
13. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance.
Zoulim F
Semin Liver Dis; 2002; 22 Suppl 1():23-31. PubMed ID: 12447726
[TBL] [Abstract][Full Text] [Related]
14. Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine.
Barcena Marugan R; Cid Gomez L; Lopez Serrano P
Transplant Proc; 2003 Aug; 35(5):1841-3. PubMed ID: 12962817
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
Da Silva LC; Pinho JR; Sitnik R; Da Fonseca LE; Carrilho FJ
J Gastroenterol; 2001 Jul; 36(7):476-85. PubMed ID: 11480792
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.
Santantonio T; Mazzola M; Iacovazzi T; Miglietta A; Guastadisegni A; Pastore G
J Hepatol; 2000 Feb; 32(2):300-6. PubMed ID: 10707871
[TBL] [Abstract][Full Text] [Related]
17. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.
Angus P; Vaughan R; Xiong S; Yang H; Delaney W; Gibbs C; Brosgart C; Colledge D; Edwards R; Ayres A; Bartholomeusz A; Locarnini S
Gastroenterology; 2003 Aug; 125(2):292-7. PubMed ID: 12891527
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus.
Walsh KM; Woodall T; Lamy P; Wight DG; Bloor S; Alexander GJ
Gut; 2001 Sep; 49(3):436-40. PubMed ID: 11511568
[TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil for hepatitis B e antigen-positive chronic hepatitis B.
Mukherjee S
N Engl J Med; 2003 Jun; 348(24):2468; author reply 2468. PubMed ID: 12802037
[No Abstract] [Full Text] [Related]
[Next] [New Search]
